US5364858A
(en)
*
|
1987-03-31 |
1994-11-15 |
Research Triangle Institute |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
US5122526A
(en)
*
|
1987-03-31 |
1992-06-16 |
Research Triangle Institute |
Camptothecin and analogs thereof and pharmaceutical compositions and method using them
|
US5053512A
(en)
*
|
1987-04-14 |
1991-10-01 |
Research Triangle Institute |
Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
|
US5227380A
(en)
*
|
1987-03-31 |
1993-07-13 |
Research Triangle Institute |
Pharmaceutical compositions and methods employing camptothecins
|
US5106742A
(en)
*
|
1987-03-31 |
1992-04-21 |
Wall Monroe E |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
US5122606A
(en)
*
|
1987-04-14 |
1992-06-16 |
Research Triangle Institute |
10,11-methylenedioxy camptothecins
|
US5180722A
(en)
*
|
1987-04-14 |
1993-01-19 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
|
US5049668A
(en)
*
|
1989-09-15 |
1991-09-17 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin analogs
|
US5340817A
(en)
*
|
1987-04-14 |
1994-08-23 |
Research Triangle Institute |
Method of treating tumors with anti-tumor effective camptothecin compounds
|
US4939255A
(en)
*
|
1987-06-24 |
1990-07-03 |
Daiichi Pharmaceutical Co., Ltd. |
Hexa-cyclic camptothecin derivatives
|
US5552154A
(en)
*
|
1989-11-06 |
1996-09-03 |
The Stehlin Foundation For Cancer Research |
Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
JP2684104B2
(ja)
*
|
1990-02-09 |
1997-12-03 |
株式会社ヤクルト本社 |
新規なカンプトテシン誘導体
|
WO1992005785A1
(en)
*
|
1990-09-28 |
1992-04-16 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogues, processes and methods
|
US5883255A
(en)
*
|
1990-10-31 |
1999-03-16 |
Smithkline Beecham Corporation |
Substituted indolizino 1,2-b!quinolinones
|
DE69233773D1
(de)
*
|
1991-02-21 |
2009-11-19 |
Smithkline Beecham Corp |
Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
|
KR930702985A
(ko)
*
|
1991-02-21 |
1993-11-29 |
스튜어트 알.슈터 |
식도암의 치료
|
DE69232852T2
(de)
*
|
1991-02-21 |
2003-09-04 |
Smithkline Beecham Corp., Philadelphia |
Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
|
US5559235A
(en)
*
|
1991-10-29 |
1996-09-24 |
Glaxo Wellcome Inc. |
Water soluble camptothecin derivatives
|
ES2086643T3
(es)
*
|
1991-10-29 |
1996-07-01 |
Glaxo Wellcome Inc |
Derivados de camptotecina solubles en agua.
|
AU671605B2
(en)
*
|
1991-11-15 |
1996-09-05 |
Smithkline Beecham Corporation |
Combination chemotherapy
|
AU2394392A
(en)
*
|
1991-12-10 |
1993-07-19 |
Smithkline Beecham Corporation |
Treatment of colorectal cancer
|
US6080751A
(en)
*
|
1992-01-14 |
2000-06-27 |
The Stehlin Foundation For Cancer Research |
Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
|
US5391745A
(en)
*
|
1992-07-23 |
1995-02-21 |
Sloan-Kettering Institute For Cancer Research |
Methods of preparation of camptothecin analogs
|
US5446047A
(en)
*
|
1992-07-23 |
1995-08-29 |
Sloan-Kettering Institute For Cancer Research |
Camptothecin analogues
|
US5614549A
(en)
*
|
1992-08-21 |
1997-03-25 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
JPH08502044A
(ja)
*
|
1992-08-21 |
1996-03-05 |
デイナ・フアーバー・キヤンサー・インステイテユート |
ヒトウイルス感染の治療
|
US5342947A
(en)
*
|
1992-10-09 |
1994-08-30 |
Glaxo Inc. |
Preparation of water soluble camptothecin derivatives
|
AP9300587A0
(en)
*
|
1992-11-12 |
1995-05-05 |
Glaxo Inc |
Water soluble camptothecin derivatives.
|
US5674872A
(en)
*
|
1993-08-20 |
1997-10-07 |
Smithkline Beecham Corporation |
Treatment of ovarian cancer
|
US5880131A
(en)
*
|
1993-10-20 |
1999-03-09 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
CA2174350A1
(en)
*
|
1993-10-20 |
1995-04-27 |
Richard B. Greenwald |
2'- and/or 7- substituted taxoids
|
US5436243A
(en)
*
|
1993-11-17 |
1995-07-25 |
Research Triangle Institute Duke University |
Aminoanthraquinone derivatives to combat multidrug resistance
|
US5447936A
(en)
*
|
1993-12-22 |
1995-09-05 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
|
GB9402934D0
(en)
*
|
1994-02-16 |
1994-04-06 |
Erba Carlo Spa |
Camptothecin derivatives and process for their preparation
|
US5468754A
(en)
*
|
1994-04-19 |
1995-11-21 |
Bionumerik Pharmaceuticals, Inc. |
11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
|
WO1995029677A1
(en)
*
|
1994-04-28 |
1995-11-09 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of camptothecin or 7-ethyl camptothecin
|
US5597829A
(en)
*
|
1994-05-09 |
1997-01-28 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of camptothecin and methods for uses thereof
|
US5604233A
(en)
*
|
1994-04-28 |
1997-02-18 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
|
US5491237A
(en)
|
1994-05-03 |
1996-02-13 |
Glaxo Wellcome Inc. |
Intermediates in pharmaceutical camptothecin preparation
|
US5834442A
(en)
*
|
1994-07-07 |
1998-11-10 |
Barbara Ann Karmanos Cancer Institute |
Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
|
US5646159A
(en)
*
|
1994-07-20 |
1997-07-08 |
Research Triangle Institute |
Water-soluble esters of camptothecin compounds
|
US6504029B1
(en)
*
|
1995-04-10 |
2003-01-07 |
Daiichi Pharmaceutical Co., Ltd. |
Condensed-hexacyclic compounds and a process therefor
|
GB9510716D0
(en)
*
|
1995-05-26 |
1995-07-19 |
Pharmacia Spa |
Substituted camptothecin derivatives and process for their preparation
|
US5663177A
(en)
*
|
1995-05-31 |
1997-09-02 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs
|
US5670500A
(en)
*
|
1995-05-31 |
1997-09-23 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs
|
US5942386A
(en)
*
|
1995-06-07 |
1999-08-24 |
Thomas Jefferson University |
Anti-fungal agents and methods of identifying and using the same
|
AU7732996A
(en)
*
|
1995-11-22 |
1997-06-11 |
Research Triangle Institute |
Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
|
US6395541B1
(en)
|
1996-05-23 |
2002-05-28 |
The Rockefeller University |
Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
|
WO1998007727A1
(en)
*
|
1996-08-19 |
1998-02-26 |
Bionumerik Pharmaceuticals, Inc. |
Highly lipophilic camptothecin derivatives
|
US6013505A
(en)
*
|
1996-10-08 |
2000-01-11 |
Smithkline Beecham Corporation |
Topoisomerase I
|
US5962303A
(en)
|
1996-10-15 |
1999-10-05 |
Smithkline Beecham Corporation |
Topoisomerase III
|
US6025156A
(en)
*
|
1996-10-15 |
2000-02-15 |
Smithkline Beecham Corporation |
Topoisomerase III
|
US6559309B2
(en)
|
1996-11-01 |
2003-05-06 |
Osi Pharmaceuticals, Inc. |
Preparation of a camptothecin derivative by intramolecular cyclisation
|
ATE329903T1
(de)
*
|
1997-02-14 |
2006-07-15 |
Bionumerik Pharmaceuticals Inc |
Hochgradig lipophile camptothecin-derivate
|
US6207673B1
(en)
|
1997-03-12 |
2001-03-27 |
The University Of North Carolina At Chapel Hill |
Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
|
ID23424A
(id)
|
1997-05-14 |
2000-04-20 |
Bayer Ag |
Glikokonjugat dari 20(s)-kamptotesin
|
US6046209A
(en)
*
|
1997-05-27 |
2000-04-04 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs
|
TW458974B
(en)
*
|
1997-07-17 |
2001-10-11 |
Kuraray Co |
Process for producing chromans
|
US6011042A
(en)
*
|
1997-10-10 |
2000-01-04 |
Enzon, Inc. |
Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
|
US6214821B1
(en)
|
1998-03-05 |
2001-04-10 |
Washington State University Research Foundation |
Methods and composition for the inhibition of cancer cells
|
EE04264B1
(et)
*
|
1998-08-05 |
2004-04-15 |
Aventis Pharma S.A. |
Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
FR2801309B1
(fr)
*
|
1999-11-18 |
2002-01-04 |
Adir |
Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US6288072B1
(en)
*
|
1999-12-29 |
2001-09-11 |
Monroe E. Wall |
Camptothecin β-alanine esters with topoisomerase I inhibition
|
BR0108728A
(pt)
|
2000-02-28 |
2003-12-30 |
Aventis Pharma Sa |
Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
|
US6548488B2
(en)
|
2000-03-17 |
2003-04-15 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
|
US6545010B2
(en)
|
2000-03-17 |
2003-04-08 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
|
AR027687A1
(es)
*
|
2000-03-22 |
2003-04-09 |
Yakult Honsha Kk |
Procedimiento para preparar camptotecina
|
US6486320B2
(en)
|
2000-09-15 |
2002-11-26 |
Aventis Pharma S.A. |
Preparation of camptothecin and of its derivatives
|
WO2002034244A2
(en)
|
2000-10-27 |
2002-05-02 |
Aventis Pharma S.A. |
A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
|
EP1335974A2
(en)
*
|
2000-11-14 |
2003-08-20 |
Emerald Biostructures Inc. |
Crystal compositions comprising topoisomerase i
|
EP2316468A1
(en)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Delivery system and methods for protecting and administering dextroamphetamine
|
US7462601B2
(en)
*
|
2002-03-26 |
2008-12-09 |
Tsutomu Kagiya |
Ameliorant for chemical treatment of cancer
|
ITRM20020306A1
(it)
*
|
2002-05-31 |
2003-12-01 |
Sigma Tau Ind Farmaceuti |
Esteri in posizione 20 di camptotecine.
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
WO2004055020A1
(en)
*
|
2002-12-16 |
2004-07-01 |
Council Of Scientific And Industrial Research |
Process for the direct preparation of 5-alkoxy and 5-acyloxy analogues of campthothecins or mappicene ketones
|
FR2852606A1
(fr)
*
|
2003-03-18 |
2004-09-24 |
Inst Nat Sante Rech Med |
Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
|
WO2004087715A1
(en)
*
|
2003-03-31 |
2004-10-14 |
Council Of Scientific And Industrial Research |
Process for preparing topotecan from 10-hydroxy-4-(s) camptothecin
|
CN100406460C
(zh)
*
|
2003-11-10 |
2008-07-30 |
中国科学院上海药物研究所 |
喜树碱的新衍生物、制备方法和用途
|
TWI333492B
(en)
*
|
2003-11-12 |
2010-11-21 |
Smithkline Beecham Cork Ltd |
Crystalline topotecan hydrochloride product and preparation thereof
|
US7422741B2
(en)
|
2004-03-05 |
2008-09-09 |
Vegenics Limited |
VEGFR-3 fusion proteins
|
RU2408387C2
(ru)
|
2004-04-27 |
2011-01-10 |
Веллстат Байолоджикс Корпорейшн |
Лечение злокачественного новообразования с применением вирусов и камптотецинов
|
US20050267141A1
(en)
|
2004-05-28 |
2005-12-01 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives
|
US20050272757A1
(en)
*
|
2004-06-04 |
2005-12-08 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
|
US7122700B2
(en)
*
|
2004-07-30 |
2006-10-17 |
Xerox Corporation |
Arylamine processes
|
WO2012050591A1
(en)
|
2010-10-15 |
2012-04-19 |
Rutgers, The State University Of New Jersey |
Hydrogel formulation for dermal and ocular delivery
|
US20090104254A1
(en)
|
2004-12-22 |
2009-04-23 |
Rutgers, The State University Of New Jersey |
Controlled Release Hydrogels
|
US20080161251A1
(en)
|
2005-01-21 |
2008-07-03 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
WO2006090931A1
(ja)
*
|
2005-02-28 |
2006-08-31 |
Eisai R & D Management Co., Ltd. |
スルホンアミド化合物の抗癌剤との新規併用
|
AU2006270297B2
(en)
*
|
2005-07-14 |
2013-01-17 |
Wellstat Biologics Corporation |
Cancer treatment using viruses, fluoropyrimidines and camptothecins
|
EP1943253A1
(en)
*
|
2005-10-10 |
2008-07-16 |
Cipla Limited |
Novel crystalline forms
|
TW200731990A
(en)
*
|
2005-12-16 |
2007-09-01 |
Sonus Pharma Inc |
Lipophilic anticancer drug compounds, compositions, and related methods
|
US7547785B2
(en)
|
2005-12-26 |
2009-06-16 |
Dr. Reddy's Laboratories Limited |
Process for preparing topotecan
|
WO2007085370A1
(en)
*
|
2006-01-25 |
2007-08-02 |
Heidelberg Pharma Ag |
9-(dimethylamino)-methyl-10-hydroxy-camptothecin lipidester derivatives
|
CN101033230B
(zh)
*
|
2006-03-10 |
2010-12-08 |
中国科学院上海药物研究所 |
一类喜树碱衍生物及其应用
|
AU2007232206B2
(en)
|
2006-03-30 |
2013-04-04 |
Drais Pharmaceuticals, Inc. |
Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
|
US20070259031A1
(en)
*
|
2006-04-26 |
2007-11-08 |
The Regents Of The University Of California |
Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
|
US20110028536A1
(en)
*
|
2006-08-18 |
2011-02-03 |
Gjerset Ruth A |
Methods and compositions for topoisomerase i modulated tumor suppression
|
EP2073803B1
(en)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US7977483B2
(en)
*
|
2007-04-11 |
2011-07-12 |
Scinopharm Taiwan, Ltd. |
Process for making topotecan
|
US20080255175A1
(en)
*
|
2007-04-16 |
2008-10-16 |
Lam Marina K |
Anti-cancer agents, compositions and methods of treating cancers
|
CA2684599C
(en)
*
|
2007-04-19 |
2013-07-02 |
Scinopharm Taiwan Ltd. |
Crystalline forms of topotecan hydrochloride and processes for making the same
|
US8026249B2
(en)
*
|
2007-09-14 |
2011-09-27 |
Deutena Pharmaceuticals, Inc. |
Deuterium-enriched topotecan
|
ITMI20072268A1
(it)
|
2007-12-04 |
2009-06-05 |
Antibioticos Spa |
Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
|
WO2009145282A1
(ja)
*
|
2008-05-29 |
2009-12-03 |
メルシャン株式会社 |
カンプトテシン誘導体の製造方法
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
US8551973B2
(en)
*
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
US8716263B2
(en)
|
2008-12-23 |
2014-05-06 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
EP3222628A1
(en)
*
|
2008-12-23 |
2017-09-27 |
Gilead Pharmasset LLC |
Nucleoside phosphoramidates
|
WO2011116026A2
(en)
|
2010-03-15 |
2011-09-22 |
The Board Of Trustees Of The University Of Illinois |
Inhibitors of beta integrin-g protein alpha subunit binding interactions
|
PT3290428T
(pt)
|
2010-03-31 |
2021-12-27 |
Gilead Pharmasset Llc |
Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
|
RU2447076C1
(ru)
*
|
2010-12-09 |
2012-04-10 |
Закрытое Акционерное Общество "Фарм-Синтез" |
Способ получения топотекана
|
EP2654754B1
(en)
|
2010-12-17 |
2016-12-21 |
Novartis AG |
Combination for treating osteosarcoma, rhabdomyosarcoma and neuroblastoma
|
US20140371258A1
(en)
|
2010-12-17 |
2014-12-18 |
Nektar Therapeutics |
Water-Soluble Polymer Conjugates of Topotecan
|
EP2655401B1
(en)
|
2010-12-20 |
2016-03-09 |
The Regents of the University of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
JP2014504638A
(ja)
|
2011-02-01 |
2014-02-24 |
グラクソスミスクライン インテレクチュアル プロパティ リミテッド |
組合せ
|
RS57350B1
(sr)
|
2011-10-03 |
2018-08-31 |
Mx Adjuvac Ab |
Nanočestice, postupak dobijanja i njihova primena kao nosača amfipatičnih ili hidrofobnih molekula u medicini, uključujući i terapiju kancera, kao i prehrambenih jedinjenja
|
PL235836B1
(pl)
*
|
2012-10-25 |
2020-11-02 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
|
CN103113381B
(zh)
*
|
2013-02-26 |
2014-12-10 |
大连理工大学 |
系列水溶性羟基喜树碱环烷胺醇衍生物及其制法与用途
|
US9907846B2
(en)
|
2013-04-01 |
2018-03-06 |
Mx Adjuvac Ab |
Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
|
EP3250609A4
(en)
|
2015-01-26 |
2018-07-11 |
The University of Chicago |
Il13ra alpha 2 binding agents and use thereof in cancer treatment
|
US20180170992A1
(en)
|
2015-01-26 |
2018-06-21 |
The University Of Chicago |
CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
|
CN108135917B
(zh)
|
2015-09-25 |
2021-07-09 |
Zy医疗 |
基于包含多糖-维生素缀合物的颗粒的药物制剂
|
BR112018068565A2
(pt)
|
2016-03-15 |
2019-02-12 |
Oryzon Genomics, S.A. |
combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
|
SI3458052T1
(sl)
*
|
2016-05-17 |
2020-04-30 |
Scandion Oncology A/S |
Kombinirano zdravljenje raka
|
AU2018314227A1
(en)
|
2017-08-07 |
2020-02-06 |
Amgen Inc. |
Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus
|
EP3669890A1
(en)
|
2018-12-18 |
2020-06-24 |
Croda International PLC |
Filamentous nanoparticles having vaccine adjuvant effect
|
WO2020191342A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
WO2020191344A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
CA3136496A1
(en)
|
2019-04-09 |
2020-10-15 |
The Board Of Trustees Of The University Of Illinois |
Drug adsorbed highly porous activated carbon for enhanced drug delivery
|
AU2020266083A1
(en)
|
2019-04-30 |
2021-09-23 |
Instituto de Medicina Molecular João Lobo Antunes |
Rank pathway inhibitors in combination with CDK inhibitors
|
US20220305081A1
(en)
|
2019-06-24 |
2022-09-29 |
Amgen Inc. |
Inhibitions of sirp-gamma for cancer treatment
|
EP4025206A1
(en)
|
2019-09-02 |
2022-07-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating pax6- deficiency related disease
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
CN116478174A
(zh)
*
|
2022-07-29 |
2023-07-25 |
杭州爱科瑞思生物医药有限公司 |
喜树碱衍生物及其制备方法和应用
|